AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Morningstar7d
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
The recent approval of Karuna's schizophrenia drug Cobenfy stands to generate multi ... ample time to bring forward the next generation of new drugs. Several of Bristol's currently marketed ...
HealthDay on MSN3d
FDA Approves Cobenfy for Adults With Schizophrenia
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
BioSpace11h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Medical Xpress3d
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.
BioPharma Dive6d
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
BioPharma Dive6d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
MedPage Today12d
Long-Term Data Support Efficacy, Safety of New Schizophrenia Drug
makes Cobenfy a highly welcomed addition for patients and providers." Approved in September, the drug was the first new class of drug for schizophrenia in over 30 years, with approval based on ...
MedCity News7d
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test
whose M1- and M4-targeting schizophrenia drug was already under FDA review. The September approval of that twice-daily pill, now named Cobenfy, made it the first muscarinic-receptor targeting drug ...
The Associated Press on MSN17d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Cobenfy also contains trospium, which blocks some of the side effects. The most common are nausea, vomiting and indigestion.